Endocrinology, Vol 136, 1097-1102, Copyright © 1995 by Endocrine Society

ARTICLES

Ligand requirements of the human corticotropin-releasing factor-binding protein

SW Sutton, DP Behan, SL Lahrichi, R Kaiser, A Corrigan, P Lowry, E Potter, MH Perrin, J Rivier and WW Vale
Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California 92138.

CRF-binding protein (CRF-BP), identified as a 37-kilodalton human serum protein, binds human (h) CRF (Kd = 0.17 +/- 0.01 nM) and blocks hCRF's ability to stimulate ACTH release by pituitary cells in vitro. The present study examines ligand requirements of CRF-BP by testing the affinity of recombinant CRF-BP for synthetic analogs of CRF and peptides in the CRF family. The relative affinities of various fragments of hCRF or related peptides for CRF-BP indicate that residues 9-28 are crucial for ligand binding. CRF-BP binds human/rat CRF and urotensin-I with high affinity, sauvagine with moderate affinity, and ovine (o) CRF with low affinity. The marked difference in the affinity of CRF-BP for oCRF (Ki = 1100 +/- 97 nM) compared to hCRF (Ki = 0.17 +/- 0.01 nM), when considered with the importance of the central domain, suggests that amino acids 22, 23, and/or 25 are critical for binding. Altering oCRF residues 22, 23, or 25 individually or collectively to match those of hCRF increases the affinity of CRF-BP for these ligands; [Ala22, Arg23, Glu25]oCRF, in which all three of these central amino acids are substituted by their hCRF counterparts, binds CRF-BP with an affinity equal to that of hCRF. CRF-BP has differential affinities for CRF receptor antagonists, binding alpha-helical CRF-(9-41) with high affinity and [D-Phe12, Nle21,38]hCRF-(12-41) with low affinity. Thus, the structural requirements for binding to CRF-BP can clearly be distinguished from those for CRF receptor recognition of both agonists and antagonists. Peptides such as hCRF-(9-33), with low biological activity but which retain high affinity for the binding protein, can competitively override the effects of CRF-BP to block CRF-induced ACTH secretion, raising the possibility that whereas endogenous CRF-BP serves to limit the distribution or duration of action of CRF, specific pharmacological inhibitors of the ligand-binding protein interaction might be used to therapeutically elevate free CRF levels.

This article has been cited by other articles:

				B. Roozendaal, G. Schelling, and J. L. McGaugh Corticotropin-Releasing Factor in the Basolateral Amygdala Enhances Memory Consolidation via an Interaction with the {beta}-Adrenoceptor-cAMP Pathway: Dependence on Glucocorticoid Receptor Activation J. Neurosci., June 25, 2008; 28(26): 6642 - 6651. [Abstract] [Full Text] [PDF]

				M. O. Huising, J. M. Vaughan, S. H. Shah, K. L. Grillot, C. J. Donaldson, J. Rivier, G. Flik, and W. W. Vale Residues of Corticotropin Releasing Factor-binding Protein (CRF-BP) That Selectively Abrogate Binding to CRF but Not to Urocortin 1 J. Biol. Chem., April 4, 2008; 283(14): 8902 - 8912. [Abstract] [Full Text] [PDF]

				E. W. Hillhouse and D. K. Grammatopoulos The Molecular Mechanisms Underlying the Regulation of the Biological Activity of Corticotropin-Releasing Hormone Receptors: Implications for Physiology and Pathophysiology Endocr. Rev., May 1, 2006; 27(3): 260 - 286. [Abstract] [Full Text] [PDF]

				N. J. Westphal and A. F. Seasholtz Gonadotropin-Releasing Hormone (GnRH) Positively Regulates Corticotropin-Releasing Hormone-Binding Protein Expression via Multiple Intracellular Signaling Pathways and a Multipartite GnRH Response Element in {alpha}T3-1 Cells Mol. Endocrinol., November 1, 2005; 19(11): 2780 - 2797. [Abstract] [Full Text] [PDF]

				M. O. Huising and G. Flik The Remarkable Conservation of Corticotropin-Releasing Hormone (CRH)-Binding Protein in the Honeybee (Apis mellifera) Dates the CRH System to a Common Ancestor of Insects and Vertebrates Endocrinology, May 1, 2005; 146(5): 2165 - 2170. [Abstract] [Full Text] [PDF]

				A. M. Chen, M. H. Perrin, M. R. DiGruccio, J. M. Vaughan, B. K. Brar, C. M. Arias, K. A. Lewis, J. E. Rivier, P. E. Sawchenko, and W. W. Vale A soluble mouse brain splice variant of type 2{alpha} corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity PNAS, February 15, 2005; 102(7): 2620 - 2625. [Abstract] [Full Text] [PDF]

				E. P. Zorrilla, L. E. Reinhardt, G. R. Valdez, K. Inoue, J. E. Rivier, W. W. Vale, and G. F. Koob Human Urocortin 2, a Corticotropin-Releasing Factor (CRF)2 Agonist, and Ovine CRF, a CRF1 Agonist, Differentially Alter Feeding and Motor Activity J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1027 - 1034. [Abstract] [Full Text] [PDF]

				O. Jahn, K. Eckart, O. Brauns, H. Tezval, and J. Spiess The binding protein of corticotropin-releasing factor: Ligand-binding site and subunit structure PNAS, September 17, 2002; 99(19): 12055 - 12060. [Abstract] [Full Text] [PDF]

				K. Eckart, O. Jahn, J. Radulovic, H. Tezval, L. van Werven, and J. Spiess A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: Implications for the design of agonists and antagonists PNAS, September 25, 2001; 98(20): 11142 - 11147. [Abstract] [Full Text] [PDF]

				K. Lewis, C. Li, M. H. Perrin, A. Blount, K. Kunitake, C. Donaldson, J. Vaughan, T. M. Reyes, J. Gulyas, W. Fischer, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor PNAS, June 19, 2001; 98(13): 7570 - 7575. [Abstract] [Full Text] [PDF]

				S. R. Smith, L. de Jonge, M. Pellymounter, T. Nguyen, R. Harris, D. York, S. Redmann, J. Rood, and G. A. Bray Peripheral Administration of Human Corticotropin-Releasing Hormone: A Novel Method to Increase Energy Expenditure and Fat Oxidation in Man J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1991 - 1998. [Abstract] [Full Text]

				M. L. Price and I. Lucki Regulation of Serotonin Release in the Lateral Septum and Striatum by Corticotropin-Releasing Factor J. Neurosci., April 15, 2001; 21(8): 2833 - 2841. [Abstract] [Full Text] [PDF]

				J. C. Bittencourt and P. E. Sawchenko Do Centrally Administered Neuropeptides Access Cognate Receptors?: An Analysis in the Central Corticotropin-Releasing Factor System J. Neurosci., February 1, 2000; 20(3): 1142 - 1156. [Abstract] [Full Text] [PDF]

				Y. E. Tian, L.-H. Wu, W. T. Mueller, and F.-Z. Chung A Screening Strategy Based on Differential Binding of Ligand to Receptor and to Binding Proteins: Screening for Compounds Interacting with Corticotrophin-Releasing Factor-Binding Protein J Biomol Screen, December 1, 1999; 4(6): 319 - 326. [Abstract] [PDF]

				M. H. Perrin, S. W. Sutton, L. A. Cervini, J. E. Rivier, and W. W. Vale Comparison of an Agonist, Urocortin, and an Antagonist, Astressin, as Radioligands for Characterization of Corticotropin-Releasing Factor Receptors J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 729 - 734. [Abstract] [Full Text]

				V. Martinez, E. Barquist, J. Rivier, and Y. Tache Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2 receptors Am J Physiol Gastrointest Liver Physiol, May 1, 1998; 274(5): G965 - G970. [Abstract] [Full Text] [PDF]

				N. Heinrich, M. R. Meyer, J. Furkert, A. Sasse, M. Beyermann, W. Bonigk, and H. Berger Corticotropin-Releasing Factor (CRF) Agonists Stimulate Testosterone Production in Mouse Leydig Cells through CRF Receptor-1 Endocrinology, February 1, 1998; 139(2): 651 - 658. [Abstract] [Full Text] [PDF]

				S. C. Heinrichs, J. Lapsansky, D. P. Behan, R. K. W. Chan, P. E. Sawchenko, M. Lorang, N. Ling, W. W. Vale, and E. B. De Souza Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal PNAS, December 24, 1996; 93(26): 15475 - 15480. [Abstract] [Full Text] [PDF]

				M. H. Perrin, W. H. Fischer, K. S. Kunitake, A. G. Craig, S. C. Koerber, L. A. Cervini, J. E. Rivier, J. C. Groppe, J. Greenwald, S. M. Nielsen, et al. Expression, Purification, and Characterization of a Soluble Form of the First Extracellular Domain of the Human Type 1 Corticotropin Releasing Factor Receptor J. Biol. Chem., August 17, 2001; 276(34): 31528 - 31534. [Abstract] [Full Text] [PDF]